Phage therapy

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Retrieved on: 
Tuesday, June 28, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Patient, Conditional sentence, Research, Biomarker, Phage therapy, U.S. Securities and Exchange Commission, Forward-looking statement, IBD, SVP, Security (finance), NYSE, DNA, SEC, Inflammatory bowel disease, Private Securities Litigation Reform Act, AI, Boehringer Ingelheim, Ingelheim am Rhein, Pharmaceutical industry

BiomX Inc. (NYSE American: PHGE) (BiomX or Company) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD).

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or Company) announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD).
  • In September 2020, Boehringer Ingelheim and BiomX entered into their first collaboration, which focused on identifying biomarkers associated with patient phenotypes in IBD.
  • We are pleased to enter into this second agreement with Boehringer Ingelheim, said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Inflammatory bowel disease is a heterogenous inflammatory condition that remains extremely difficult to treat.

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Retrieved on: 
Monday, June 27, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Department, CF, Patient, Conditional sentence, Valencia CF Foundation, Pseudomonas aeruginosa, Therapy, Phage therapy, U.S. Securities and Exchange Commission, Forward-looking statement, Mortality, Part, Pharmacokinetics, Cystic Fibrosis Foundation, Food, NYSE, FEV1, Pediatrics, Cystic fibrosis, SEC, Private Securities Litigation Reform Act, Safety, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Pharmaceutical industry

We are pleased to reach this important clinical milestone in our cystic fibrosis program, said Jonathan Solomon, Chief Executive Officer of BiomX.

Key Points: 
  • We are pleased to reach this important clinical milestone in our cystic fibrosis program, said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Despite the significant advancements made in the treatment of cystic fibrosis, P. aeruginosa remains a leading cause of patients' morbidity and mortality.
  • BiomX is developing BX004 for the treatment of CF patients with chronic respiratory infections caused by Pseudomonas aeruginosa, a main contributor to morbidity and mortality in patients with CF.
  • In September 2021, BX004 was cleared by the U.S. Food and Drug Administration to initiate a Phase 1b/2a study in CF patients with chronic respiratory infections caused by Pseudomonas aeruginosa.

AMPRIUS TECHNOLOGIES TO PRESENT AT CANTOR FITZGERALD TECHNOLOGY ESG CONFERENCE ON JUNE 29TH

Retrieved on: 
Thursday, June 23, 2022
SEC filing, SEC, Registration statement, Conference, Sale, Silicon, Prospectus, Business, Acquisition, Four Seasons Hotel Philadelphia, Security (finance), Four Seasons Hotels and Resorts, Risk, Government, Name, Phage therapy, THE, Forward-looking statement, Cell, Failure, Register, Season, Securities Act of 1933, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, New, Communication, Business architecture, Technology, U.S. Securities and Exchange Commission, NYSE, Probability, CA, PARTIES

FREMONT, Calif., June 23, 2022 /PRNewswire/ -- Amprius Technologies, Inc. ("Amprius"), the leader in lithium-ion batteries with its Si Nanowire Anode Platform, is scheduled to present at the Cantor Fitzgerald Technology ESG Conference, to be held at the Four Seasons Hotel in East Palo Alto, CA, from June 27 through June 29, 2022.

Key Points: 
  • FREMONT, Calif., June 23, 2022 /PRNewswire/ -- Amprius Technologies, Inc. ("Amprius"), the leader in lithium-ion batteries with its Si Nanowire Anode Platform, is scheduled to present at the Cantor Fitzgerald Technology ESG Conference, to be held at the Four Seasons Hotel in East Palo Alto, CA, from June 27 through June 29, 2022.
  • To schedule a one-on-one meeting, request a conference invitation or receive additional information, please contact your conference representative or Amprius' investor relations team at (949) 574-3860 [email protected] .
  • Amprius Technologies, Inc. is a leading manufacturer of high-energy and high-power lithium-ion batteries producing the industry's highest energy density cells.
  • These forward-looking statements include, but are not limited to, statements regarding the proposed business combination between Amprius and Kensington (the "Proposed Business Combination").

Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis

Retrieved on: 
Wednesday, May 18, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Infectious Diseases, Clinical Trials, Diabetes, Risk, PST, Infection, DFO, MD, American Diabetes Association, Multimedia, Patient, Phage therapy, Therapy, Trial of the century, NIH, FDA, United States Department of Defense, Time, APT, Osteomyelitis, Safety, Technology, National, Amputation, Investigational New Drug, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220518005275/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220518005275/en/
    Vial of phage from APTs phage bank for evaluation in treatment of bacterial infections.
  • Phages from the APT phage bank are precision-matched to the patients infections through a proprietary phage susceptibility test (PST) that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.
  • APT has ongoing clinical trials to address substantial unmet patient needs in Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO).

CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Retrieved on: 
Tuesday, January 4, 2022
Research, Infectious Diseases, Clinical Trials, Philanthropy, Other Health, Biotechnology, Pharmaceutical, Health, Foundation, Science, People, Safety, Hearing loss, National, Drug of last resort, CF, Infection, Pseudomonas, Diagnosis, Risk, Clinical trial, Pseudomonas aeruginosa, Bacteria, Food, Nature, Phage therapy, Conditional sentence, Mark (given name), MD, Research, Valencia CF Foundation, Virus, Food and Drug Administration Amendments Act of 2007, Patient, Cystic Fibrosis Foundation, Bacteriophage, Investigational New Drug, Respiratory tract, Cystic fibrosis, Environment, Pharmaceutical industry, Foundation

The Foundation has supported several phage studies to explore the feasibility of phage therapy as a treatment for drug-resistant infections in CF.

Key Points: 
  • The Foundation has supported several phage studies to explore the feasibility of phage therapy as a treatment for drug-resistant infections in CF.
  • Although promising results have been reported in several individual cases, studies like this one will help us evaluate the safety and efficacy of phage as a potential therapy.
  • Rigorous clinical studies are needed to assess the safety and efficacy of phage for potential wider use in CF.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Safety, CF, CFF, Private Securities Litigation Reform Act, Conditional sentence, U.S. Securities and Exchange Commission, Mortality, Pseudomonas aeruginosa, Forward-looking statement, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmacokinetics, SEC, NYSE, Therapy, Valencia CF Foundation, Patient, Cystic Fibrosis Foundation, Phage therapy, Disease, Security (finance), Part, Atopic dermatitis, Colorectal cancer, Inflammatory bowel disease, Cystic fibrosis, Primary sclerosing cholangitis, Pharmaceutical industry

BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (CF Foundation).

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (CF Foundation).
  • We are very pleased to receive the support of the Cystic Fibrosis Foundation an organization which historically has played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF), said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Under the terms of the agreement with the CF Foundation, BiomX will receive up to $5 million in two tranches.
  • In the first tranche, which closed on December 21, 2021, the CF Foundation invested $3 million as initial equity investment.

Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress

Retrieved on: 
Thursday, November 4, 2021
MSD, Medication, DEL, Time, Armata, Drug development, Merck, NYSE, Staphylococcus aureus, GMP, Phage therapy, Congress, Pseudomonas aeruginosa, Infection, Drug, Urinary tract infection, Therapy, Pharmaceutical industry

In its seventh year, the Congress will attract more than 400 attendees from around the world and features more than 150 speakers.

Key Points: 
  • In its seventh year, the Congress will attract more than 400 attendees from around the world and features more than 150 speakers.
  • It is the world's largest and most commercially focused gathering of antimicrobial resistance stakeholders globally.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

Retrieved on: 
Tuesday, November 2, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Safety, MHS, Duke University School of Medicine, MD, Sponsor, Diagnosis, Technology, University, Disease, Johns Hopkins School of Medicine, WRAIR, NIH, Duke University, Partnership, Person, Infection, Patient, Pseudomonas aeruginosa, FDA, Licensure, UC San Diego School of Medicine, Phage therapy, PST, Urinary tract infection, NIAID, Leadership, Risk, United States Department of Defense, National, University of California, San Diego Performance-Based Skills Assessment, Investigational New Drug, Cystic fibrosis, University of California, Pediatrics, Multimedia, Bacteria, APT, AMR, Program, National Institute, Therapy, Division, Health, Associate, Walter Reed Army Institute of Research, Bacteriophage, National Institute of Allergy and Infectious Diseases, Pharmaceutical industry

Under the agreement, APT will provide proprietary bacteriophages for use in the NIAID sponsored Phase 1b/2 clinical study.

Key Points: 
  • Under the agreement, APT will provide proprietary bacteriophages for use in the NIAID sponsored Phase 1b/2 clinical study.
  • We are honored and excited to partner with ARLG as they undertake efforts to address a significant unmet medical need related to cystic fibrosis.
  • Through FDA emergency use allowance, we have observed the potential of phage therapy as an effective treatment for cystic fibrosis patients with Pseudomonas aeruginosa lung infections.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility

Retrieved on: 
Tuesday, November 2, 2021
MSD, Medication, DEL, Drug development, Merck, AP, NYSE, Staphylococcus aureus, GMP, Phage therapy, SEC, Communication, Pseudomonas aeruginosa, Annual report, Forward-looking statement, Risk, Company, Clinical trial, Infection, COVID-19, Therapy, Bacteriophage, Pharmaceutical industry

"Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata.

Key Points: 
  • "Armata's innovative phage therapy pipeline will be enhanced by our commitment to build out a new R&D facility that offers expanded GMP manufacturing capacity to support future pivotal studies and commercial launch," stated Dr. Brian Varnum, Chief Executive Officer of Armata.
  • "In addition, we believe this new, state-of-the-art facility is essential for our novel product form given the scarcity of phage-specific manufacturing capacity.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing its bacteriophage-based technology with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

CRISPR Based Therapeutics Market Trends and Global Forecasts 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 9, 2021
General Health, Health, Oncology

The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global Forecasts 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The "CRISPR Based Therapeutics Market, 2021-2030" report features an extensive study of the current market landscape and future opportunity for the players involved in the development of CRISPR based therapeutics for the treatment of a variety of disease conditions.
  • One of the key objectives of the report was to estimate the future growth potential of CRISPR based therapeutics market, over the coming decade.
  • It also includes information on the completed, ongoing and planned clinical trials for CRISPR based therapeutics, sponsored by various industry players.